Literature DB >> 2418504

Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

F di Marzo Veronese, T D Copeland, A L DeVico, R Rahman, S Oroszlan, R C Gallo, M G Sarngadharan.   

Abstract

Approximately 80 percent of all human sera that react with antigens of HTLV-III, the etiologic agent of the acquired immune deficiency syndrome (AIDS), recognize protein bands at 66 and 51 kilodaltons. A mouse hybridoma was produced that was specific to these proteins. Repeated cloning of the hybridoma did not separate the two reactivities. The p66/p51 was purified from HTLV-III lysates by immunoaffinity chromatography and subjected to NH2-terminal Edman degradation. Single amino acid residues were obtained in 17 successive degradation cycles. The sequence determined was a perfect translation of the nucleotide sequence of a portion of the HTLV-III pol gene. The purified p66/51 had reverse transcriptase activity and the monoclonal immunoglobulin G specifically removed the enzyme activity from crude viral extract as well as purified enzyme.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418504     DOI: 10.1126/science.2418504

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  156 in total

1.  Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.

Authors:  P O Falnes; R Welker; H G Kräusslich; S Olsnes
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase.

Authors:  G Tachedjian; H E Aronson; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Insertion of a peptide from MuLV RT into the connection subdomain of HIV-1 RT results in a functionally active chimeric enzyme in monomeric conformation.

Authors:  P K Pandey; N Kaushik; T T Talele; P N Yadav; V N Pandey
Journal:  Mol Cell Biochem       Date:  2001-09       Impact factor: 3.396

4.  Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase.

Authors:  J G Julias; A L Ferris; P L Boyer; S H Hughes
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Ty3 integrase is required for initiation of reverse transcription.

Authors:  M Henrietta Nymark-McMahon; Nadejda S Beliakova-Bethell; Jean-Luc Darlix; Stuart F J Le Grice; Suzanne B Sandmeyer
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is modulated by residue 294 of the small subunit.

Authors:  Z Sevilya; S Loya; N Adir; A Hizi
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

7.  The nature of the N-terminal amino acid residue of HIV-1 RNase H is critical for the stability of reverse transcriptase in viral particles.

Authors:  Guney Boso; Claes Örvell; Nikunj V Somia
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

8.  Mutations in the 5' end of the human immunodeficiency virus type 1 polypurine tract affect RNase H cleavage specificity and virus titer.

Authors:  Mary Jane McWilliams; John G Julias; Stefan G Sarafianos; W Gregory Alvord; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Purification and characterization of an active human immunodeficiency virus type 1 RNase H domain.

Authors:  J S Smith; M J Roth
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.